

*The National Academies of*  
**SCIENCES • ENGINEERING • MEDICINE**

HEALTH AND MEDICINE DIVISION  
BOARD ON POPULATION HEALTH AND PUBLIC HEALTH PRACTICE

**Committee on Prevention and Control of Sexually Transmitted Infections  
in the United States  
Meeting 3: October 7, 2019**

---

**SPEAKER BIOSKETCHES**

---

**Emilie Alirol, Ph.D., M.S.,** is STI Project Leader at the Global Antibiotic Research & Development Partnership (GARDP). She started to work with the Drugs for Neglected Diseases initiative (DNDi) in August 2016, joining GARDP as a Project Advisor. In January 2017 she transitioned to a Senior Clinical Trial Manager position, working on both the Sexually Transmitted Infections (STIs) and Neonatal sepsis programs. Since 2018, she is leading the STI program. Prior to this, she worked as Clinical Trial Manager of an MSF-sponsored trial on Multi-Drug Resistant Tuberculosis (MDR-TB). Emilie obtained her Ph.D. in molecular biology from the University of Geneva in 2006. She also holds a Masters of Science in Epidemiology from the London School of Hygiene and Tropical Medicine (LSHTM). She started her career as a Clinical Research Scientist with the Geneva University Hospitals, where she focused on infectious diseases research. She has been involved in both therapeutic and diagnostic studies, and has managed several investigator-initiated trials, from phase 2 to 4. Since 2011 Emilie has also been engaged in training and education on clinical trials. Emilie was an Ethics Committee member for 6 years and the vice chair of the WHO Research Ethics Review Committee from 2014 to 2017.

**Eliav Barr, M.D.,** joined Merck & Co., Inc. in 1995 and in 1998 became the head of the Human Papilloma Virus (HPV) vaccine clinical program. He developed the clinical/regulatory strategy for the program; designed and managed 17 clinical studies involving over 30,000 subjects worldwide; developed a program to evaluate the economic impact and long-term efficacy of the HPV vaccine, and oversaw analyses of key clinical studies. Between 2010 and 2018, Eliav assumed positions of greater responsibility for infectious diseases and vaccines clinical development at Merck Research Laboratories. He currently heads Merck's Global Medical Affairs Department.

**José A. Bauermeister, M.P.H., Ph.D.,** is a Penn Presidential Professor at the University of Pennsylvania, with appointments in the School of Nursing, the Department of Psychiatry at the Perelman School of Medicine, and the Department of Gender, Sexuality & Women's Studies at the School of Arts & Sciences. He holds a bachelor's in psychology from the University of Puerto Rico, a joint MPH/PhD in Public Health from the University of Michigan, and postdoctoral fellowship in Psychiatry at Columbia University. Dr. Bauermeister is a Fellow of the Aspen Institute's 2019 class of Health Innovators Fellows, and member of the Aspen Global Leadership Network. Dr. Bauermeister's research career has focused on developing interdisciplinary, multilevel HIV/STI prevention strategies for young sexual and gender

minorities. He has secured an international reputation as a top scholar in sexuality and technology-delivered HIV/STI interventions, as evidenced by over 200 scientific publications and funding track-record of over \$25 million as principal investigator and another \$115 million as co-investigator in federally-funded research. Dr. Bauermeister serves a member of the Penn Center for AIDS Research's Executive Committee, and holds leadership positions in the National Institutes of Health's Adolescent Medicine Trials Network for HIV/AIDS Interventions and the NIH Microbicide Trials Network. Based on his expertise, he serves in the Editorial Boards of PLoS One, Youth & Adolescence, Archives of Sexual Behavior, AIDS and Behavior, American Journal of Community Psychology, and AIDS Education & Prevention.

**Kim M. Blankenship, Ph.D.,** is Professor in the Department of Sociology and Associate Dean of Research in the College of Arts and Sciences at American University, and Co-director of the Social and Behavioral Sciences Core of the District of Columbia Center for AIDS Research. She previously served on the faculty of Sociology at Duke University and at the Duke Global Health Institute (2008-2010) and on the faculty at Yale University, where she was also Associate Director of the Center for Interdisciplinary Research on AIDS (1998-2008). Research and publications focus on the social determinants of health, with a particular emphasis on intersecting social inequalities of race, class and gender and structural interventions to address them. She has received funding from NIDA, NIMH, CDC, and the Bill & Melinda Gates Foundation (BMGF). Current research focuses on the intersecting impacts of mass incarceration, housing policy, housing stability and HIV/STI related risk. She has also conducted research on the implementation and impact of community mobilization interventions for HIV prevention in female sex workers in India.

**Laura W. Cheever, M.D.,** is Associate Administrator of the HIV/AIDS Bureau at the Health Resources and Services Administration (HRSA) where she provides leadership and technical expertise in the administration of the Ryan White HIV/AIDS Program and in HRSA's global HIV/AIDS program. Upon joining HRSA in 1999, she served as the national director of the Ryan White AIDS Education and Training Center program. Her priorities are to end the HIV epidemic in the U.S. through increasing access to HIV care and improving outcomes, integrating substance abuse treatment into HIV care, and eliminating Hepatitis C infection among co-infected patients. Previously, Dr. Cheever was an Assistant Professor at Johns Hopkins University where she developed a regional HIV program to provide on-site HIV care in health departments serving 18 Maryland counties. Dr. Cheever has served as medical director of both a women's methadone program and a peer-based adherence program and directed provider training for the Johns Hopkins AIDS Service. Dr. Cheever has worked internationally and with the President's Emergency Plan for AIDS Relief since its inception. She continues to provide clinical care for patients living with HIV and is a member of the Department of Health and Human Services HIV Treatment Guidelines for Adults and Adolescents.

**Liz Chen, Ph.D., M.P.H.,** is an assistant professor in the Department of Health Behavior at the UNC Gillings School of Global Public Health and also serves as the Health Behavior MPH Concentration Lead. Dr. Chen has a decade of experience as a teacher, public health practitioner, and researcher and earned both her MPH and PhD degrees in this department. Dr. Chen's research interests are at the intersection of adolescent health, technology and design thinking. Her current research focuses on understanding the acceptability of health applications (i.e. apps)

among adolescents to ensure that health apps developed for adolescent populations are more likely to be adopted in the real world. Dr. Chen is also the Design Thinking Lead for UNC through the Office of Innovation, Entrepreneurship, and Economic Development. In 2016, she was trained in human-centered design at the world renowned design firm IDEO in San Francisco. Through her training, she spent 18 months applying design thinking mindsets and methods to develop a technological solution to teen pregnancy. In 2017, she co-founded the tech nonprofit MyHealthEd, Inc. whose mission is to use human-centered design to improve the health and well-being of youth of every identity. Its first product Real Talk is a mobile app that uses real stories by real teens to convey relevant and credible information about health topics to teens and reassures them that they are not alone. Real Talk has reached more than 14,500 teens and has been featured in Fast Company and Teen Vogue. Dr. Chen was named to the 2018 Forbes 30 Under 30 class for Social Entrepreneurs and in May 2019, she facilitated the Chancellor's Faculty Entrepreneurship Workshop on design thinking for 40 UNC faculty who were nominated by their deans. Dr. Chen earned her undergraduate degree in Anthropology from Princeton University and served as a high school science teacher through Teach For America before starting her public health training.

**Harrell Chesson, Ph.D.**, is a health economist in the Division of STD Prevention at the Centers for Disease Control and Prevention. He received his B.A. in economics from the University of North Carolina at Chapel Hill in 1990 and his Ph.D. in economics from Duke University in 1996. He joined CDC in 1996 as a Prevention Effectiveness Fellow. His research focuses on the impact and cost-effectiveness of STD prevention programs and policies.

**Carolyn D. Deal, Ph.D.**, is Chief of the Enteric and Sexually Transmitted Infections Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH. Her prior positions were Deputy Director of the Division of Bacterial Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA and Research Microbiologist at the Walter Reed Army Institute of Research. She received a B.S. in Biology from Purdue University in West Lafayette, IN and a Ph.D. in Microbiology from the University of Illinois, Urbana-Champaign followed by a post-doctoral fellowship at Scripps Research Institute in La Jolla, CA. Dr. Deal has a strong interest in product development, encompassing vaccines, therapeutics and diagnostics. In addition to her work at NIAID, she collaborates with the World Health Organization on efforts to advance efforts in global vaccine development and implementation, strategies and products for the diagnosis, control and prevention of STIs and Enteric Infections, and monitoring of emergence of gonococcal antimicrobial resistance.

**Carol S. Jimenez, J.D.**, is Deputy Director for Strategic Initiatives at the Office of Infectious Disease and HIV/AIDS Policy (OIDP) in the U.S. Department of Health and Human Services (HHS). OIDP as well as HHS' other public health offices is under the leadership of the Office of the Assistant Secretary for Health. OIDP provides strategic leadership and management, while encouraging collaboration, coordination, and innovation among federal agencies and stakeholders to reduce the burden of infectious diseases nationwide. Ms. Jimenez leads OIDP's Division of HIV, Viral Hepatitis and Sexually Transmitted Infections (STI). Ms. Jimenez was a practicing health care attorney for almost 30 years prior to joining the federal government in 2010. Before joining OIDP, Ms. Jimenez spent four years at the Center for Medicare &

Medicaid Services (CMS), implementing the Affordable Care Act for the private health insurance market. Following her work at CMS, Ms. Jimenez was Deputy Director of the HHS Office of Minority Health. Ms. Jimenez holds a law degree from Georgetown University and a bachelor degree from University of Rochester.

**Brenda Korte, Ph.D.**, specializes in the development and evaluation of point-of-care technologies for use in primary care, home health, and rural health settings. She spent 13 years as a Program Director at the National Institute of Biomedical Imaging and Bioengineering, where she established and managed the Point-of-Care Technologies Research Network and created a range of technology development initiatives aimed at improving health care access and healthy independent living. Prior to this, she worked as a technology transfer professional and as an industry researcher specializing in patient monitoring and anesthesia delivery. She has experience establishing multidisciplinary collaborations between government agencies, research institutions, medical device companies, professional organizations and clinical and user groups to support technology development efforts. A major focus of her work across all these roles has been the creation of information resources to assist decision makers with prioritizing projects, allocating resources, and making strategic choices. In 2014, Dr. Korte left the NIH to start POC Device Consulting to develop resources and tools to assist health care providers with making adoption decisions on point-of-care technologies. Dr. Korte received a Ph.D. in Physical Chemistry from the University of Colorado, Boulder.

**Seth C. Kalichman, Ph.D.**, is a Clinical-Community Psychologist and Professor of Psychological Sciences at the University of Connecticut. Professor Kalichman dedicates his research to preventing the spread of HIV and caring for those affected by the HIV epidemic. His research is concentrated in the southeastern United States and South Africa. His work has been continuously and exclusively funded by the National Institutes of Health since 1992. He was previously on the faculties of Loyola University of Chicago, Georgia State University, and the Medical College of Wisconsin. He is currently the Director of the Southeast HIV/AIDS Research and Evaluation (SHARE) Project, an HIV behavioral research program based in Atlanta and Macon, Georgia. His research in South Africa is in collaboration with the South African Medical Research Council. Professor Kalichman serves on NIH grant review panels, has over 450 peer-reviewed journal articles, and has authored and edited nine books in the area of HIV prevention, including *HIV-Treatment as Prevention (TasP): Primer for Behavior-Based Implementation* and *Denying AIDS: Conspiracy Theories, Pseudoscience & Human Tragedy*. Interventions developed by his research team have been widely disseminated by the Centers for Disease Control and Prevention, including *Healthy Relationships*, *Nia*, *In the Mix*, and *Phone-Delivered Support Counseling for HIV Treatment Adherence*. He is Editor-in-Chief of the peer-reviewed research journal *AIDS and Behavior* published by Springer-Nature. Professor Kalichman was the recipient of the 1997 Early Career Award in Health Psychology from the American Psychological Association and the 2005 Distinguished Scientist Award from the Society for Behavioral Medicine.

**John Pachankis, Ph.D.**, is Susan Dwight Bliss Associate Professor of Public Health at Yale, where he directs Yale's LGBTQ Mental Health Initiative. His goal is to bring effective mental health treatments to LGBTQ people around the world and to identify strategies for overcoming the significant barriers that exist to getting such treatment to LGBTQ people in greatest

need. With funding from the U.S. National Institutes of Health, he develops and examines the efficacy of LGBTQ-affirmative interventions delivered via novel technologies (e.g., smartphones), in diverse settings (e.g., Eastern Europe, Appalachia), and with diverse segments of the LGBTQ community (e.g., rural youth, queer women, men of color). These treatments have shown strong and sustained reductions in depression, anxiety, suicidality, substance use disorders, and HIV/STI risk across several randomized controlled trials. Dr. Pachankis has published over 100 scientific papers on LGBTQ mental health and stigma. He recently co-edited the *Handbook of Evidence-Based Mental Health Practice with Sexual and Gender Minorities* published by Oxford University Press. His research has had national and international scholarly, legal, and popular impact and he has received several awards from the American Psychological Association including awards for Distinguished Contributions to the Advancement of Psychotherapy, Distinguished Contributions to Psychology in the Public Interest, and Distinguished Scientific Contribution to LGBTQ Research.

**Manos Perros, Ph.D.**, has served as Entasis Therapeutics' chief executive officer, co-founder, and director since May 2015. Prior to this, Dr. Perros worked for AstraZeneca AB as vice president and head of its infection research and early development organization from 2010 to 2015 and as site head for its research center in Waltham, Massachusetts from 2012 to 2015. Prior to joining AstraZeneca, Dr. Perros served as director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as vice-president and chief scientific officer, antivirals, at Pfizer, Inc. A chemist by training, Dr. Perros conducted his Ph.D. work in Belgium, France and Germany, and was an associate in the Biophysics department at Yale from 1993 to 1995. Dr. Perros received the PhRMA Discoverer's Award in 2010.

**Susan Sherman, Ph.D.**, is a Professor in the Department of Health, Behavior, and Society who focuses on improving the health of marginalized populations, particularly that of drug users and sex workers. She is interested in the structural drivers of health and risk in both the conduct of observational and intervention research. She has over 17 years of experience in developing and evaluating HIV prevention, peer-outreach behavioral and microenterprise interventions in Baltimore, Pakistan, Thailand, and India. She is the Co-Director of the Baltimore HIV Collaboratory and a part of the Executive Leadership Committee of the Johns Hopkins Center for AIDS Research. She co-leads the Addiction and Overdose workgroup of the Bloomberg American Health Initiative. She is the PI of a study that examines the role of the police on the STI/HIV risk environment of street-based sex workers and includes the first cohort of sex workers in the US. She is also evaluating an innovative pre-booking diversion program for low level drug offenders. She has a new study which focusing on the effects of a structural level intervention with sex workers in Baltimore, which will create a full service drop-in center for sex workers in Baltimore. She serves on several Baltimore City and state advisory commissions on syringe exchange and overdose prevention initiatives, as well as the Board Secretary of the National Harm Reduction Coalition.